Biontech Rna Pharmaceuticals Gmbh

Universitaet Duisburg-Essen

Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz

Dirk Schadendorf

Martina Fatho

Volker Lennerz

Thomas Woelfel

Daniela Eberts

Hakim Echchannaoui

Annette Paschen

Catherine Woelfel

Silke Luebcke

Silke Lübcke

Thomas Wölfel

Catherine Wölfel

Anette Paschen

Silke LÜBCKE

The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention. The invention further pertains to pharmaceutical compositions, especially vaccine compositions, comprising the antigens, nucleic acids, binding agents or T cells in accordance with the invention, and methods for the generation of T cells, which are specifically reactive to the antigens of the invention in an MHC-independent manner.

MHC-independent tumor-associated antigens

T cell receptors with MHC independent binding to GM-CSF receptor alpha chain

Growing community of inventors

Essen, Germany

Dirk Schadendorf